IL1A and COVID-19: Although several studies have already been performed to investigate the potential immunoregulatory roles of anti-IL-1 agents such as anakira for treating severe COVID-19, the use of rilonacept as an IL-1 decoy receptor binding to IL-1β and IL-1α has not yet been explored by preclinical and clinical trial studies [100].